Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease

Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients with ADPKD, eGFR≥60 ml/...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Soc Nephrol
Auteurs principaux: Tesar, Vladimir, Ciechanowski, Kazimierz, Pei, York, Barash, Irina, Shannon, Megan, Li, Ray, Williams, Jason H., Levisetti, Matteo, Arkin, Steven, Serra, Andreas
Format: Artigo
Langue:Inglês
Publié: American Society of Nephrology 2017
Sujets:
Clinical Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5661280/
https://ncbi.nlm.nih.gov/pubmed/28838955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016111232
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires